Achievement of Treat-to-Target Thresholds with Envudeucitinib, a Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Results from STRIDE and OLE
Main Article Content
Keywords
next-generation oral, envudeucitinib, ESK-001, Treat-To-Target
References
2. Mahil SK et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a realworld, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158-1166.
3. Gisondi P et al. Treat-to-Target Approach for the Management of Patients with Moderate-toSevere Plaque Psoriasis: Consensus Recommendations. Dermatol Ther (Heidelb). 2021;11(1):235-252.
4. Golbari NM et al. Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. J Eur Acad Dermatol Venereol. 021;35(2):417-421.
5. Blauvelt A et al. Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, doubleblinded, placebo-controlled, dose-ranging phase 2 study. J Am Acad Dermatol. 2025:S0190
9622(25)02466-1.
6. Blauvelt et al. EADV2025 Poster Presentation.
https://www.alumis.com/file.cfm/18/docs/eadv_late_breaker_presentation_final.pd
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.